Hydroxychloroquine in vitro against SARS-CoV-2 [abstract]
ncbi.nlm.nih.gov
ncbi.nlm.nih.gov
RESULTS: Hydroxychloroquine (EC50=0.72 μM) was found to be more potent than chloroquine (EC50=5.47 μM) in vitro. Based on PBPK models results, a loading dose of 400 mg twice daily of hydroxychloroquine sulfate given orally, followed by a maintenance dose of 200 mg given twice daily for 4 days is recommended for SARS-CoV-2 infection, as it reached three times the potency of chloroquine phosphate when given 500 mg twice daily 5 days in advance.
CONCLUSIONS: Hydroxychloroquine was found to be more potent than chloroquine to inhibit SARS-CoV-2 in vitro.“
can someone make sense of this?
>RESULTS: Hydroxychloroquine (EC50=0.72 μM) was found to be more potent than chloroquine (EC50=5.47 μM) in vitro.<
EC50 is the effective concentration 50%, this means the dose that yields the desired effect in 50% of the subjects/individuals, cells,etc
------------------------------------------------------
>Based on PBPK models results, a loading dose of 400 mg twice daily of hydroxychloroquine sulfate given orally, followed by a maintenance dose of 200 mg given twice daily for 4 days is recommended for SARS-CoV-2 infection, as it reached three times the potency of chloroquine phosphate when given 500 mg twice daily 5 days in advance.<
this is saying that comparing the EC50 to a pharmaco-kinetic model suggests an oral dosage regime that will produce the EC in blood plasma that was observed to be effective
--------------------------------------------------------
>CONCLUSIONS: Hydroxychloroquine was found to be more potent than chloroquine to inhibit SARS-CoV-2 in vitro.“<
the lower EC50 of Hydroxychloroquine leads to a 3fold increase of effect vs a larger dosage of chloroquine, in the cultured cell model
---------------------------------------------------------